Beam Therapeutics (BEAM) Liabilities and Shareholders Equity (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $1.5 billion in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 0.95% year-over-year to $1.5 billion in Q1 2026; TTM through Mar 2026 was $5.7 billion, a 13.21% increase from a year earlier, with the FY2025 full-year figure at $1.5 billion, up 34.19% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $1.5 billion, roughly flat from $1.5 billion in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for BEAM reached as high as $1.5 billion in Q4 2025 and fell as low as $1.1 billion in Q4 2024.
• Historically, Liabilities and Shareholders Equity has averaged $1.4 billion across 5 years, with a median of $1.4 billion in 2023.
• Across the five-year window, Liabilities and Shareholders Equity surged 109.65% in 2022 and declined 24.38% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $1.3 billion in 2022, then climbed by 8.79% to $1.5 billion in 2023, then dropped by 24.38% to $1.1 billion in 2024, then soared by 34.19% to $1.5 billion in 2025, then fell by 0.03% to $1.5 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $1.5 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.3 billion in Q3 2025.